PPCB logo

Propanc Biopharma, Inc.

PPCB
Healthcare|Biotechnology|AU
$1.77
+0.13 (+7.93%)
DCF Value
$3.50
Tangible Book / Share
$83.67
Cash / Share
$7.40
Financing Filings (last 12 months)
8
Shelf registrations / offering prospectuses — latest Oct 5, 2026 (S-1). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer
Nov 2, 2026 · GlobeNewsWire
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
Oct 30, 2026 · GlobeNewsWire
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
Oct 28, 2026 · GlobeNewsWire
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
Oct 26, 2026 · GlobeNewsWire
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Oct 22, 2026 · GlobeNewsWire
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Oct 22, 2026 · GlobeNewsWire
Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
Oct 16, 2026 · GlobeNewsWire
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
Oct 14, 2026 · GlobeNewsWire
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib
Oct 7, 2026 · GlobeNewsWire
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Sep 29, 2026 · GlobeNewsWire

SEC Filings (60)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 29, 20268-KMaterial eventDocumentIndex
Oct 21, 2026DEF 14CDocumentIndex
Oct 8, 2026PRE 14CDocumentIndex
Oct 5, 2026S-1IPO / offering registrationDocumentIndex
Sep 25, 202610-KAnnual reportDocumentIndex
Aug 21, 2026DEF 14CDocumentIndex
Aug 5, 2026PRE 14CDocumentIndex
Jul 27, 2026EFFECTDocumentIndex
Jul 17, 2026S-1IPO / offering registrationDocumentIndex
Jul 14, 20268-KMaterial eventDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
Apr 20, 2026EFFECTDocumentIndex
Apr 10, 2026S-1IPO / offering registrationDocumentIndex
Mar 31, 2026DEF 14CDocumentIndex
Mar 20, 2026PRE 14CDocumentIndex
Mar 19, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 6, 2026424B3Offering prospectusDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Feb 24, 2026EFFECTDocumentIndex
Feb 19, 2026S-1/AIPO / offering registrationDocumentIndex
Feb 17, 202610-QQuarterly reportDocumentIndex
Feb 2, 2026S-1IPO / offering registrationDocumentIndex
Jan 30, 2026424B3Offering prospectusDocumentIndex
Jan 9, 2026EFFECTDocumentIndex
Jan 7, 20268-KMaterial eventDocumentIndex
Dec 30, 2025S-1IPO / offering registrationDocumentIndex
Dec 29, 2025DEF 14CDocumentIndex
Dec 10, 2025PRE 14CDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 202510-QQuarterly reportDocumentIndex
Nov 10, 20258-KMaterial eventDocumentIndex
Oct 14, 20258-KMaterial eventDocumentIndex
Sep 29, 202510-KAnnual reportDocumentIndex
Aug 19, 20258-KMaterial eventDocumentIndex
Aug 19, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 18, 2025424B3Offering prospectusDocumentIndex
Aug 18, 2025424B4Offering prospectusDocumentIndex
Aug 14, 2025CERTDocumentIndex
Aug 13, 2025EFFECTDocumentIndex
Aug 13, 20258-A12BDocumentIndex